The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Denosumab Linked to Rebound-Associated Fractures in Nine Patients

Denosumab Linked to Rebound-Associated Fractures in Nine Patients

October 21, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients can develop rebound-associated vertebral fractures after stopping denosumab, a new report of nine cases shows.

You Might Also Like
  • Undetected Fractures Linked to Back Pain in Older Men
  • Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

All of the patients were considered to be at low risk of fracture, and the fractures occurred within nine to 16 months of their last injection, Dr. Olivier Lamy and colleagues from Lausanne University Hospital in Switzerland report.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Studies are urgently needed to determine: 1) the pathophysiological processes involved; 2) the clinical profile of patients at risk for rebound-associated vertebral fractures; and 3) the management and/or treatment regimens after denosumab discontinuation,” Dr. Lamy and his team wrote in a paper online October 12 in the Journal of Clinical Endocrinology and Metabolism.

Denosumab is approved for treating osteoporosis and for preventing loss of bone in patients on certain cancer treatments. Side effects can include osteonecrosis of the jaw and atypical femoral fracture, the authors note, but the optimal treatment duration with denosumab has not been defined.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There is no rebound effect after bisphosphonate discontinuation, the authors add, but discontinuation of denosumab is associated with severe bone turnover rebound (BTR) and rapid loss of bone mineral density (BMD). Earlier in 2016, they reported severe spontaneous vertebral fractures in three patients after discontinuation of denosumab. In the current report, they describe these cases and six more patients with rebound-associated vertebral fractures at their hospital.

Dr. Lamy and colleagues note that they treat about 200 patients per year with denosumab. They also identified 32 women with osteoporosis who stopped taking the drug and did not develop vertebral fractures; 26 had been treated with bisphosphonates before or after taking denosumab.

It may be possible to reduce or prevent BTR with denosumab by administering bisphosphonates before or after treatment with the drug, based on their own clinical experience, the researchers note.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The expected compliance of patient and the resources to guarantee medical examination at regular intervals should be considered before starting denosumab treatment,” they add. “However, oncedenosumab is started, it should be scrupulously given every six months.”

They call for randomized controlled trials to investigate the role of pre- and post-treatment with bisphosphonates in decreasing rebound-associated vertebral fractures after denosumab discontinuation.

“In the meantime, health authorities, physicians and patients must be aware of this . . . risk, anddenosumab injections must be scrupulously done every six months, but not indefinitely,” the researchers conclude.

Dr. Lamy did not respond to an interview request by press time.

Reference

Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab. 2016 Oct 12:jc20163170. [Epub ahead of print].

 

Filed Under: Conditions, Professional Topics Tagged With: bone mineral density (BMD), bone turnover rebound (BTR), denosumab, Fractures, Osteoporosis, osteoporosis treatments, vertebral fracture

You Might Also Like:
  • Undetected Fractures Linked to Back Pain in Older Men
  • Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.